A Melbourne-based biopharmaceutical company was the best performer on the Australian Securities Exchange in 2023 as its treatments for debilitating early childhood neurodevelopmental disorders progressed. The value of Neuren Pharmaceuticals shares more than tripled this year - making it the biggest gainer among the 500 companies in the All Ordinaries. That came as after its therapy for Rett syndrome won US approval in March and its treatment candidate for Pitt Hopkins, Phelan-McDermid and Angelman syndromes showed promise in three separate clinical trials. Neuren was also made a member of the ASX200 in September and expects to make…
